Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 51,299

Document Document Title
WO/2017/187338A1
The present invention relates to pharmaceutically acceptable complex formulation comprising complexes of Lumacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/187340A1
The invention is directed to a pharmaceutical combination composition comprising stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lum...  
WO/2017/187336A1
The present invention relates to pharmaceutically acceptable complex formulations comprising complexes of Ivacaftor, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the pr...  
WO/2017/181994A1
The present invention relates to the fields of organic chemistry and pharmacology. Specifically, the present invention relates to a new himbacine analogue, the compound having a structure represented by formula (II), relates to a stereoi...  
WO/2017/182908A1
The present invention relates to pharmaceutical compositions of Apixaban or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients and process for its preparation. The compositions were prepared by conventio...  
WO/2017/181653A1
A radix sanguisorbae sapogenin polymeric micelle, prepared from the following raw materials and accessories in proportion by weight: 30 parts of radix sanguisorbae sapogenin and 100-5,000 parts of mPEG-PLA-Phe (Boc). The radix sanguisorb...  
WO/2017/181993A1
The present invention relates to the fields of organic chemistry and pharmacology. Specifically, the present invention relates to a new himbacine analogue, the compound having a structure represented by formula (I), relates to a stereois...  
WO/2017/183217A1
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...  
WO/2017/181988A1
Provided are a traditional-Chinese-medicine composition effective in treating various conditions, and derivative thereof and product thereof; the compound consists of 1-3 parts by weight of processed licorice, raw licorice, Chinese date,...  
WO/2017/183215A1
[Problem] To provide, as a substitute for a clinically used injected drug (5-azacytidine or 2'-deoxy-5-azacytidine), a 5-azacytidine or 2'-deoxy-5-azacytidine prodrug having high stability against the metabolic enzyme cytidine deaminase,...  
WO/2017/177668A1
A ziyuglycoside II polymer micelle, prepared by the following raw material and excipient in parts by weight: 20 parts of ziyuglycoside II, and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality assessment experiments indicate that the prepared...  
WO/2017/180807A1
Systems and methods for providing a clotting factor VIII (CFVIII) dosing regimen include collecting two blood samples from a patient after an infusion of CFVIII and determining a CFVIII clearance based on the two blood samples, and deter...  
WO/2017/181177A1
The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia)...  
WO/2017/177934A1
Applications of a hyacinth bletilla extract or a konjak extract in the preparation of drugs for preventing and/or treating leukopenia. The hyacinth bletilla extract comprises hyacinth bletilla polysaccharide, and the konjak extract compr...  
WO/2017/178316A1
This invention relates to the use of a bacterium of the genus Bifidobacterium, particularly, but not exclusively, a bacterium of the Bifidobacterium animalis ssp. lactis strain 420 (B420) for use in reducing food, energy and/or fat intake.  
WO/2017/180648A1
Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlle...  
WO/2017/177104A1
The present invention relates to a reconstitution solution for spray dried plasma having a non-anticoagulant compound that does not bind calcium. When the reconstitution solution of the present invention is mixed with spray dry plasma, t...  
WO/2017/174017A1
A proprotein convertase subtilisin kexin type 9 (PCSK9) binding protein with a unique complementarity-determining region and specific binding activity, and application thereof. The binding protein can specifically bind to PCSK9 to effect...  
WO/2017/175010A1
There is herein provided an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, as described in the description, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thromb...  
WO/2017/173993A1
A composition comprising an essential oil part and a carrier oil part, wherein the essential oil is derived from a plant. The genus of the plant is selected from a group consisting of Matricaria, Citrus, Origanum, Rosmarinus, Juniperus a...  
WO/2017/175013A1
There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more ph...  
WO/2017/172887A1
Use of a poly-oxygenated metal hydroxide composition comprising a clathrate containing free oxygen gas (02) molecules in the preparation of a solution for increasing interstitial tissue oxygenation PO2. In some embodiments, the poly-oxyg...  
WO/2017/172898A1
A colloid or crystalline solution with the addition of a poly-oxygenated metal hydroxide comprising a clathrate compound having free O2 gas molecules. The oxygen enabled solution is configured to oxygenate the interstitial tissue of a ma...  
WO/2017/170860A1
The purpose of the present invention is to provide a heat shock protein 47 inhibitor which inhibits the collagen-binding function of heat shock protein 47 that is essentially required for extracellular secretion of collagen. Provided is ...  
WO/2017/167150A1
The present invention provides a 3-fluoropyridine heterocyclic compound. The 3-fluoropyridine heterocyclic compound and a pharmaceutically acceptable salt thereof have a structure as shown in formula I. Further provided in the present in...  
WO/2017/170765A1
Provided are: a novel nitrogen-containing heterocyclic compound, which has an aldosterone synthase-inhibiting activity and, therefore, is useful for preventing and/or treating various diseases or symptoms associated with aldosterone and/...  
WO/2017/172893A1
A composition of a poly-oxygenated metal hydroxide comprising a clathrate containing oxygen gas molecules having particles sized of less than or equal to 3 um in diameter. The composition particles sized at 3 um and less can deposit into...  
WO/2017/173027A1
The presently disclosed subject matter provides methods for reducing sickling of an erythrocyte comprising sickle hemoglobin (HbS) by introducing polynucleotide aptamers into the erythrocyte. The polynucleotide aptamers specifically bind...  
WO/2017/173290A1
In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comp...  
WO/2017/162791A1
The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXl antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity ...  
WO/2017/162103A1
Disclosed is a preparation method for an azacitidine injection, wherein each azacitidine injection comprises 100 mg of azacitidine and 100 mg of mannitol. The preparation method comprises the steps of measuring 80% water for injection, a...  
WO/2017/164257A1
The present invention provides a mesoderm induction method including a step for bringing pluripotent stem cells and bone morphogenetic protein 4 (BMP4) or CHIR into contact for three days or longer.  
WO/2017/162798A1
The present invention relates to novel therapeutic ways for treating Wolfram Syndrome (WS) by targeting the neuronal calcium sensor 1 (NCS1). The present inventors have demonstrated that WFS1, which loss of function is responsible of the...  
WO/2017/161621A1
Disclosed is the use of an antiplatelet thrombolysin in the preparation of a medicine for treating thrombotic thrombocytopenic purpura (TTP). The main pathogenesis of TTP is a von Willebrand factor-cleaving protease, namely, a congenital...  
WO/2017/160890A1
CRISPR/CAS-related compositions and methods for treatment of beta hemoglobinopathies are disclosed.  
WO/2017/159655A1
[Problem] To provide a peptide that binds strongly to immunoglobulin G (IgG). [Solution] This peptide has the amino acid sequence represented by SEQ ID NO:1. In said amino acid sequence: the 16th amino acid (X16) from the amino acid of t...  
WO/2017/153520A1
A compound of formula I: (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from H, halo, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, C1-4 alkyloxy, NH-C1-4 alkyl and cyano; R2a and R2b are indepen...  
WO/2017/152237A1
The present invention relates to new Desferrioxamine B-based compounds that are useful for iron-chelation therapy, to their preparation, and to compositions including the compounds. The present invention also relates to the use of the co...  
WO/2017/153521A1
A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...  
WO/2017/153513A1
A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from the group consisiting of H, halo, C1-4 alkoxy, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, NH-C1-4 alkyl and cyano; R2a...  
WO/2017/153519A1
A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH;...  
WO/2017/153220A1
This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and ...  
WO/2017/153515A1
A compound of formula (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from H, halo, methyl and methoxy; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me;...  
WO/2017/153518A1
A compound of formula (Ia), (Ib) or (Ic) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...  
WO/2017/151746A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or d...  
WO/2017/150477A1
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...  
WO/2017/151042A1
A pharmaceutical composition for adminstration of Dabigatran etexilate through the mucous membranes of the oral cavity, characterized in that the composition comprises a therapeutically effective amount of Dabigatran etexilate and a solu...  
WO/2017/151018A1
The invention relates to the chemistry of organic compounds, pharmacology and medicine, and pertains to the prevention and/or treatment of a state in mammals characterized by undesirable thrombosis, and, in particular, thromboses, thromb...  
WO/2017/150637A1
The present invention inhibits, in an artificial red blood cell containing purified and enriched hemoglobin that substantially has no enzymatic activity to reduce methemoglobin, transformation of the hemoglobin into methemoglobin. Provid...  
WO/2017/147078A1
Methods and compositions that can be used to modulate the activity of furin in a subject are disclosed herein. In some embodiments, the methods include administering a pharmaceutical composition including a protease inhibitor. In some em...  

Matches 301 - 350 out of 51,299